Search
The Newsletter
The Principals
Reports
Conferences
Databases
Custom Research
Contact Us
Home
 

Online Report Subscribers, Click Here
Pricing and Ordering Information

  

U.S. Markets for Skin Replacements and Substitutes and Active Wound Repair Modulators
Report #A140 - February 2013
121 Pages – 22 Exhibits – 9 Company Profiles

In 2011, U.S. sales of tissue-engineered skin replacements/substitutes and active wound repair modulators totaled approximately $404.8 million; of this, skin replacements/substitutes (including traditional products that are used for a broad range of indications including cosmetic and reconstructive surgery, as well as future introductions of tissue-engineered skin replacement/substitute products for a variety of wound healing applications) accounted for an estimated 78.1% of sales, and active wound repair modulators (consisting only of growth factors, the only FDA approved product in this market to date) accounted for the remaining 21.9% of sales. Over the forecast period covered by this report, combined sales are expected to increase at a compound annual rate of 6.3%, reaching an estimated $549.7 million in the year 2016.

This new report from Medtech Insight includes analyses of products, technologies, current and forecast markets, competitors, and opportunities in the U.S. skin replacements/substitutes and active wound repair modulators market. Topics discussed in this report include an overview of clinical issues in wound management, tissue-engineered skin replacements/substitutes (e.g., epidermal equivalents, dermal equivalents, and multilayer equivalents), active wound repair modulators (e.g., growth factors, gene therapy agents, stem cells, antibiotics/anti-infectives, hormones, matrix metalloproteinase inhibitors, and neuropeptides), analyses of market forecasts and market shares, and profiles of leading competitors and products in these markets.

Ordering Information

Title

 Report# Publication
Date		 List Price

U.S. Markets for Skin Replacements and Substitutes and Active Wound Repair Modulators

A140

February 2013

$3,750
Order Online:
Single User only (Please call for corporate subscription pricing)		 PDF Only

Print versions of Reports are available upon request for an additional fee.

Methodology

Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.

 

TABLE OF CONTENTS

 

EXECUTIVE SUMMARY

i.       Tissue-Engineered Skin Replacements/Substitutes

ii.       Active Wound Repair Modulators

a.      Growth Factors

b.      Gene Therapy

c.      Stem Cells

iii.      Combined Market Forecast

 

Exhibit ES-1:    Tissue-Engineered Skin Replacements and Substitutes, Market Forecast, 2011-2016

Exhibit ES-2:    Growth Factors, Market Forecast, 2011-2016

Exhibit ES-3:    Tissue-Engineered Skin Replacements/Substitutes and Active Wound Repair Modulators, Combined Market Forecast, 2011-2016

 

1. CLINICAL ISSUES IN WOUND MANAGEMENT

1.1 Physiology of Wound Closure

1.1.1 Layers of the Skin and Supporting Structures

1.1.1.1 Epidermis

1.1.1.2 Dermis

1.1.1.3 Hypodermis

1.1.1.4 Fascia

1.1.1.5 Muscle

1.1.1.6 Bone

1.1.2 Wound Closure Process

1.1.2.1 Hemostasis

1.1.2.2 Inflammation

1.1.2.3 Proliferation

1.1.2.4 Remodeling Phase

1.2 Factors Affecting Wound Closure

1.2.1 Intrinsic Factors

1.2.1.1 Age and Chronic Illness

1.2.1.2 Body Composition

1.2.1.3 Nutritional Status

1.2.2 Extrinsic Factors

1.2.2.1 Ambient Temperature

1.2.2.2 Desiccation/Hydration

1.2.2.3 Infection

1.2.2.4 Maceration

1.2.2.5 Medication and Other Treatment Modalities

1.2.2.6 Necrotic Tissue and Debris

1.2.2.7 Oxygen

1.2.2.8 Stress

1.2.2.9 Wound Creation and Depth

1.2.2.10 Wound Closure Techniques

1.2.2.11 Other Extrinsic Factors

1.2.3 Complications of Wound Healing

1.2.3.1 Scarring

1.2.3.2 Bleeding

1.3 Wound Types

1.3.1 Illness-Related Wounds

1.3.1.1 Etiology

1.3.1.1.1 Arterial Ulcers

1.3.1.1.2 Diabetic Ulcers

1.3.1.1.3 Venous Ulcers

1.3.1.2 Epidemiology

1.3.2 Pressure Ulcers

1.3.2.1 Etiology

1.3.2.2 Epidemiology

1.3.3 Surgical Wounds

1.3.3.1 Etiology

1.3.3.2 Epidemiology

1.3.4 Traumatic Wounds

1.3.4.1 Etiology

1.3.4.1.1 Abrasions, Contusions, and Lacerations

1.3.4.1.2 Amputations

1.3.4.1.3 Burns

1.3.4.2 Epidemiology

 

Exhibit 1-1:      The Skin’s Layers and Supporting Structures

Exhibit 1-2:      Phases of the Wound Closure Process

Exhibit 1-3:      Intrinsic and Extrinsic Factors Affecting Wound Closure

Exhibit 1-4:      Illness-Related Wounds, Facts and Figures, 1996-2006, and 2009

Exhibit 1-5:      Pressure Ulcers, Facts and Figures, 1996-2006, and 2009

Exhibit 1-6:      Stages of Pressure Ulcers

Exhibit 1-7:      Surgical Wounds, Facts and Figures, 1996-2006, and 2009

Exhibit 1-8:      Lacerations and Other Types of Traumatic Wounds, Facts and Figures, 1996-2006, and 2009

Exhibit 1-9:      Amputations, Facts and Figures, 1996-2006, and 2009

Exhibit 1-10:    Burns, Facts and Figures, 1996-2006, and 2009

Exhibit 1-11:    Classification of Burns, by Mechanism of Injury

Exhibit 1-12:    Classification of Burns, by Extent of Injury

 

2. TISSUE-ENGINEERED SKIN REPLACEMENTS AND SUBSTITUTES

2.1 Allografts

2.2 Autografts

2.3 Xenografts

2.4 Autologous and Tissue-Engineered Skin Replacements/Substitutes

2.4.1 Epidermal Equivalent Products

2.4.2 Dermal Equivalent Products

2.4.3 Multilayer Equivalent Products

2.5 Market Forecast

2.6 Competitive Analysis

 

Exhibit 2-1:      2013, Selected Current and Emerging Tissue-Engineered Skin Replacements and Substitutes

Exhibit 2-2:      Tissue-Engineered Skin Replacements and Substitutes, Market Forecast, 2011-2016

Exhibit 2-3:      2011, Tissue-Engineered Skin Replacements and Substitutes Market, Share by Supplier

 

3. ACTIVE WOUND REPAIR MODULATORS

3.1 Growth Factors

3.1.1 Growth Factor Classification

3.1.1.1 Fibroblast Growth Factors

3.1.1.2 Transforming Growth Factors

3.1.1.3 Epidermal Growth Factors

3.1.1.4 Platelet-Derived Growth Factors

3.1.1.5 Insulin-Like Growth Factors

3.1.1.6 Keratinocyte Growth Factors

3.1.1.7 Vascular Endothelial Growth Factors

3.1.1.8 Autologous Growth Factors

3.1.1.8.1 Arteriocyte Medical Systems

3.1.1.8.2 Biomet

3.1.1.8.3 Cytomedix

3.1.1.8.4 Harvest Technologies/Terumo

3.1.1.9 Summary of Angiogenic Growth Factors

3.1.2 Competitors and Products

3.1.3 Market Forecast

3.2 Gene Therapy Agents

3.3 Stem Cells

3.3.1 Types of Stem Cells

3.3.1.1 Embryonic Stem Cells

3.3.1.2 Adult Stem Cells

3.3.1.3 Cord Blood Stem Cells

3.3.2 The Role of Stem Cells in Wound Healing

3.3.3 Market Status

3.4 Other Active Wound Repair Modulators and Pharmaceuticals

3.4.1 Antibiotics and Anti-Infectives

3.4.2 Hormones

3.4.3 Matrix Metalloproteinase Enzyme Inhibitors

3.4.4 Neuropeptides in Diabetic Wounds

3.4.5 Other Products

 

Exhibit 3-1:      Selected Growth Factors in Development for Wound Healing Applications

Exhibit 3-2:      The Angiogenesis Process

Exhibit 3-3:      2012, Selected Angiogenic Growth Factors

Exhibit 3-4:      Growth Factors, Market Forecast, 2011-2016

 

4. COMPANY PROFILES

4.1       Biomet, Inc.

4.2       Forticell Bioscience, Inc.

4.3       Genentech, Inc./F. Hoffmann-La Roche LTD

4.4       Genzyme Corporation/Sanofi SA

4.5       Integra LifeSciences, Inc./ Integra LifeSciences Holdings Corporation

4.6       LifeCell Corporation/Kinetic Concepts, Inc.

4.7       Organogenesis, Inc.

4.8       Smith & Nephew PLC

4.9       TEI Biosciences, Inc.

 

APPENDIX:  COMPANY LISTING

 

To order reports or obtain information about special pre-publication offers from within the U.S., contact reports@elsevier.com. You can also call 1.949.453.0071 (or toll-free within the U.S. at 1.888.290.2225) or fax 1.949.453.0072.

 

The Newsletter | The Principals | Reports | Conferences | Physician Surveys | Consulting | Contact Us | Home